Introduction {#Sec1}
============

Oesophageal cancer is the 19th most common cancer in the European Union (EU) \[[@CR1]\], with 45 900 new cases diagnosed in 2012. It represents 1% of the total cancer in the EU \[[@CR1]\]. The main histology is Oesophageal Squamous Cell Carcinoma (SCC), which represents 90% of oesophageal cancers worldwide, and Oesophageal Adenocarcinoma (OA), of which mortality rate has increased in several countries in the EU \[[@CR2]\]. For patients with limited disease, the reference treatment is surgical resection \[[@CR3]\]. For patients unable to undergo surgery, because of a locally advanced disease or a surgical contraindication, the reference treatment is chemoradiotherapy \[[@CR3], [@CR4]\], i.e. a combination of FOLFOX/ cisplatin-FU and 5-6 weeks radiotherapy (1.8-2 Gy/fraction, 5 days per week) \[[@CR3]\]. Despite a decreasing rate of mortality (by 7% for EU men and 3% for EU women) \[[@CR2]\], the prognosis remains poor with a median overall survival of 17.5-20.5 months \[[@CR5]\]. Several prognostic factors have been studied in oesophageal cancer, especially nutritional factors \[[@CR6]--[@CR8]\]. Di Fiore et al showed that baseline nutritional status was predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer (LAOC) \[[@CR9]\].

Sarcopenia is defined by a loss of skeletal muscle mass with or without loss of fat mass \[[@CR10]\]. Prado et al showed that sarcopenia at baseline, assessed by CT-scan of Skeletal Muscle Area (SMA) on the third lumbar vertebra, is a powerful prognostic factor for solid tumours of the respiratory and gastrointestinal tracts \[[@CR11], [@CR12]\].It is associated with reduced physical function \[[@CR13]\], poor tolerance to anticancer therapy \[[@CR14]--[@CR17]\], and worse prognosis \[[@CR18]\]. In operated oesophageal cancer patients, sarcopenia was associated to increased incidence of surgical complications and worse overall survival \[[@CR19]--[@CR22]\]. There are few studies on patients treated with chemoradiotherapy. A recent Japanese retrospective study shows the pejorative impact of pretherapeutic sarcopenia for patients with a LAOC \[[@CR23]\]. We report a single-center retrospective analysis of 97 patients having received chemo-radiotherapy for LAOC. The presence of sarcopenia was assessed by automatically delineating the skeletal muscle area on CT slices at 3rd lumbar vertebra level retrieved a posteriori from staging ^18^FDG-PET/CT.

Methods {#Sec2}
=======

Patients and procedures {#Sec3}
-----------------------

### Objective(s) {#Sec4}

A single-center study was performed at the Centre Henri Becquerel (Rouen, France). The population included all new LAOC patients referred to the Radiotherapy and Medical Physics department between October 5, 2005 and June 5, 2012. The inclusion criteria were: histologically confirmed oesophageal cancer, pre-therapeutic ^18^FDG-PET/CT with available images, and curative-intent chemo-radiotherapy. Surgical resection of residual tumour after chemo-radiotherapy was allowed.

The following baseline clinical data were collected: age, sex, WHO performance status, histological subtypes, TNM stage, and cancer location. The baseline nutritional parameters were: weight, size, Body Mass Index (BMI), weight loss history, serum albumin level, and the Buzby Nutritional Risk Index (NRI) \[[@CR24]\]. We also collected treatment characteristics including the chemotherapy protocol and radiotherapy data (total dose, treatment duration). Finally, we collected imaging data from ^18^FDG-PET/CT, such as the Standardized Uptake Value Maximum (SUV ~Max~), Total Volume of 40% of SUVmax segmentation (Tvol40), SUVmean, and Total Lesion Glycolysis (TLG).

Sarcopenia was assessed by a homemade plugin running on our institutional Picture Archiving and Communication System (PACS, Telemis version 4.7, Telemis SA, Louvain la Neuve, Belgium). The skeletal muscles were automatically delineated by fixed thresholds (− 29 to + 150 Hounsfield Unit) \[[@CR25]\] on two adjacent cross-sectional CT images acquired at the third lumbar vertebra (L3) and extracted from the staging ^18^FDG-PET/CT. The L3 skeletal muscles were the psoas, quadratus lumborum, paraspinal and abdominal wall muscles. The mean of the delineated surfaces on both images was defined as skeletal muscle L3 area (cm^2^). All delineations were visually checked and, if necessary, corrected by a single observer (RM). The Skeletal Muscle Index was calculated by dividing the skeletal muscle area by the squared height (SMI, cm^2^/m^2^) \[[@CR25]\]. Sarcopenia was defined as SMI \< 52.4cm^2^/m^2^ for men and \< 38.5 cm^2^/m^2^ for women \[[@CR26]\]. We also measured were the Mean Muscular Density (MMDL3, HU), the Visceral Fat Mass (VFML3, cm^2^) and the Subcutaneous Fat Mass (SCFML3, cm^2^) (Fig. [1](#Fig1){ref-type="fig"}). The cut-off values for SUVmax and Tvol40 by univariate analysis were based on Palie et al. \[[@CR27]\]. Fig. 1Example of SML (red), SCFML (blue) and VFM (yellow), measured on a cross-sectional images of the third lumbar vertebra

The primary endpoint was overall survival, defined as the time from the start of the radiotherapy to death or last follow-up. Secondary endpoints were to define optimal cut-off values to predict the overall survival for SCFML3, VFML3 and mean muscular density.

All patients were irradiated at the Centre Henri Becquerel. Concomitant chemotherapy was delivered in the referring hospitals (CHU Rouen, CH Dieppe, CHI Elbeuf).

Statistical analysis {#Sec5}
--------------------

Sarcopenic and non-sarcopenic patients were compared by Fisher's exact and Pearson's chi-square tests for categorical data, and by independent samples *t* tests or Mann-Whitney tests as appropriate for quantitative data. Survival probabilities were estimated by the Kaplan-Meier method and compared with the log-rank test. Univariate and multivariate analyses of variables associated to variations in survival were performed using the Cox model. In order to respect the TRIPOD criteria, the performance of the retained model was validated internally by a bootstrap method (1b statement). The Concordance index (C-index) was computed to assess discrimination between observed and predictive data. Predictive accuracy of death by SMI, SCFM, or VFM was assessed by Receiver Operating Characteristics ROC analysis. Optimal cut-off values were computed by maximizing predictive performance criteria (sensitivity Se, specificity Sp, Positive and Negative Predictive Values PPV and NPV). Two-sided tests and confidence intervals were reported at the 5% level of significance. All statistical analyses were performed using R software version 3.3.3 using the "survival" package for survival analysis, "boot" package for bootstrap analysis, and "ROCR" and "OptimalCutpoints" packages for ROC analysis.

### Ethics and deontology {#Sec6}

The study protocol RTEP3 has been approved by the Centre Henri Becquerel Cancer ethics committee ([www.becquerel.fr](http://www.becquerel.fr)).

Results {#Sec7}
=======

From October 5, 2005 to June 5, 2012, 98 LAOC patients were referred for radiotherapy and 97 had available PET-CT images.

The overall characteristics of patients are shown in Table [1](#Tab1){ref-type="table"}. A total of 194 CT L3 cross-sectional images were analysed. Fifty-four (56%) patients were classified as sarcopenic, and 43 (44%) as non-sarcopenic. Table [2](#Tab2){ref-type="table"} shows a predominance of male patients (81 men, 84%) and squamous cell carcinomas (77%). Sarcopenia was more prevalent in men than in women (49/81 (60%) vs 5/16 (31%), *p* = 0.05) and in squamous cell carcinomas (48/75 (64%) vs. 6/22 (27%), *p* = 0.04). The patients with sarcopenia had lower weights (mean 65 \[15.2\] kg. vs. 75 \[12.3\], *p* \< 0.001), lower Body Mass Index BMI (22 \[4.7\] kg/m^2^ vs. 27 \[4.2\], *p* \< 0.001), and larger weight loss (8% \[0--32\] vs. 5% \[0--16\], *p* = 0.02). The differences in albumin serum levels (38.42 \[5.3\] vs. 39.62 \[39.6\], *p* = 0.3) and Buzby NRI (97 \[64--113\] vs 101 \[78--117\], *p* = 0.08) were not statistically significant. Table 1Overall Characteristics of the populationNo. of patients, ***n*** = 97**Clinical parametersAge**63.61 (11.12)**Sex**  M81 (83.5%)  F16 (16.5%)**Histological subtype**  SCC75 (77.3%)  OA22 (22.7%)**T**  213 (14.4%)  374 (82.2%)  43 (3.3%)**N**  015 (15.6%)  175 (78.1%)  24 (4.2%)  32 (2.1%)**M**  080 (82.5%)  117 (17.5%)**TNM Stage**  I-II25 (25.7%)  III-IV72 (74.2%)**Tumour location**  Upper20 (20.6%)  Mean35 (36.1%)  Low42 (43.3%)**WHO Stage**  046 (47.4%)  145 (46.4%)  \> 16 (6.2%)**Nutritional parametersNRI**  \> 97.541 (52.6%)  97.5--83.532 (41.0%)  \< 83.55 (6.4%)**Albumin levels (g/l)**38.91 (5.14)**Weight (kg)**69.39 (14.84)**Size (m)**1.7 \[1.45--1.85\]**BMI**24.08 (5.00)**Weight loss (%)**7.00 \[0.00--32\]**Anthropometric parametersSML3 (cm**^**2**^**)**143.57 (29.15)**VFML3 (cm**^**2**^**)**109.33 \[5.80, 418.29\]**SCFML3 (cm**^**2**^**)**121.43 \[4.20, 432.99\]**Mean Density (HU)**30.59 (7.64)**SMI**49.59 (8.72)^**18**^**FDG-PET/CT parametersTVol40**13.50 \[1.90, 140.40\]**SUVmean**6.30 \[1.90, 16.60\]**SUVmax**11.50 \[3.60, 27.90\]**TLG**94.5 \[6.9--1294\]Note: Qualitative variable are described by distribution and frequencies (%); Gaussian variables are described by mean and standard deviation; non-Gaussian variables are described by mean \[range\]*Abbreviation*: *SCC* Squamous Cell Carcinoma, *OA* Oesophageal adenocarcinoma, *NRI* nutritional risk index, *BMI* Body Mass Index, *SML3* L3 Skeletal Muscular Mass, *VFML3* L3 Visceral Fat Mass, *SCFML3* L3 Subcutaneous Fat Mass, *SMI* Skeletal Muscle Index, *TNM* Tumour, Node, Metastasis, *WHO* World Health Organization, *TLG* Total Lesion GlycolysisTable 2Comparison between sarcopenic and non-sarcopenic patientsNon Sarcopenic, ***n*** = 43 (%)Sarcopenic, ***n*** = 54 (%)p**Clinical parametersAge**61.84 (10.90)65.06 (11.20)0,158**Sex**0,061  M32 (74.4%)49 (90.7%)  F11 (25.6%)5 (9.3%)**Histological subtype**0,005  SCC27 (62.8%)48 (88.9%)  OA16 (37.2%)6 (11.1%)**T**0,177  10 (0%)0 (0%)  28 (20.0%)5 (10.0%)  332 (80.0%)42 (84.0%)  40 (0.0%)3 (6.0%)**N**0,567  09 (20.9%)6 (11.3%)  132 (74.4%)43 (81.1%)  21 (2.3%)3 (5.7%)  31 (2.3%)1 (1.9%)**M**0,066  039 (90.7%)41 (75.9%)  14 (9.3%)13 (24.1%)**TNM Stage**0,053  I-II15 (34.9%)10 (18.6%)  III-IV28 (65.1%)44 (81.5%)**Tumour location**0,151  Upper6 (14.0%)14 (25.9%)  Mean14 (32.6%)21 (38.9%)  Low23 (53.5%)19 (35.2%)**WHO Stage**\< 0.001  029 (67.4%)17 (31.5%)  111 (25.6%)34 (63.0%)  23 (7.0%)2 (3.7%)  30 (0.0%)1 (1.9%)**Nutritional parametersNRI**0,167   \> 97.521 (65.6%)20 (43.5%)  97.5--83.510 (31.2%)22 (47.8%)   \< 83.51 (3.1%)4 (8.7%)**Albumin levels (g/l)**39.62 (4.91)38.42 (5.28)0,301**Weight (kg)**75.23 (12.29)64.74 (15.15)\< 0.001**Size (m)**1.70 \[1.52, 1.85\]1.71 \[1.45, 1.81\]0,112**BMI**26.52 (4.24)22.14 (4.73)\< 0.001**Weight loss (%)**5.00 \[0.00, 16.00\]8.00 \[0.00, 32.00\]0,018**Anthropometric parametersSML3 (cm**^**2**^**)**158.78 (31.28)131.45 (20.64)\< 0.001**VFML3 (cm**^**2**^**)**139.85 \[10.70, 418.29\]82.06 \[5.80, 415.74\]0,005**SCFML3 (cm**^**2**^**)**145.89 \[55.13, 432.99\]81.94 \[4.20, 419.88\]\< 0.001**Mean Density (HU)**31.33 (7.40)30.00 (7.85)0,398**SMI**55.47 (8.12)44.91 (5.93)\< 0.001^**18**^**FDG-PET/CT parametersSUVmax**11.20 \[4.90, 26.40\]12.15 \[3.60, 27.90\]0,17**TVol40**12.60 \[2.00, 70.00\]17.85 \[1.90, 140.40\]0,111**SUVmean**6.00 \[1.90, 16.60\]7.10 \[2.90, 16.50\]0,112**TLG**69.20 \[7.40, 482.50\]121.50 \[6.90, 1294.00\]0,044Note: Qualitative variable are described by distribution and frequencies (%); Gaussian variables are described by mean and standard deviation; non-Gaussian variables are described by mean \[range\]*Abbreviation*: *SCC* Squamous Cell Carcinoma, *OA* Oesophageal adenocarcinoma, *NRI* nutritional risk index, *BMI* Body Mass Index, *SML3* L3 Skeletal Muscular Mass, *VFML3* L3 Visceral Fat Mass, *SCFML3* L3 Subcutaneous Fat Mass, *SMI* Skeletal Muscle Index, *TNM* Tumour, Node, Metastasis, *WHO* World Health Organization, *TLG* Total Lesion Glycolysis

There were 76 deaths out of 97 patients, 50/54 (93%) in the sarcopenic population versus 26/43 (61%) in the non-sarcopenic population. The overall median survival was 27 (4--121) months, 22 months in the sarcopenic patients and 61 months in the non-sarcopenic patients (Fig. [2](#Fig2){ref-type="fig"}). There were 17 patients with metastasis (17.5%), of whom 4 were non-sarcopenic patients (23.5%) and 13 were sarcopenic (76.5%) (*p* = 0.06). Fig. 2Overall survival of sarcopenic and non-sarcopenic patients

Univariate analysis (Table [3](#Tab3){ref-type="table"}) shows an increased risk of death in patients with sarcopenia (Hazard Ratio HR 2.61 \[95% Confidence Interval 1.61--4.24\], *p* \< 0.001), BMI \< 21 (1.67 \[1.03--2.73\], *p* = 0.037), and NRI \< 97.5 (1.71 \[1.04--2.81\], *p* = 0.033). The risk of death was lower in WHO = 0 patients (0.63 \[0.4--0.99\], *p* = 0.04). A multivariate analysis including these factors (Table [4](#Tab4){ref-type="table"}) showed that sarcopenia was the only significant prognostic factor (HR 2.32 \[1.24--4.34\], *p* = 0.008). The model was found to have acceptable concordance during internal validation with C-index of 0.64 \[0.56--0.72\] based on 1000 bootstrap replicates. Table 3Hazard ratio and 95%CI for proportional hazard models assessing the effect of variables associated with survival (univariate analysis)Coefficient (SE)Hazard ratio (95%CI)pBMI \< =210.51 (0.25)1.67 (1.03--2.73)0.037NRI \< =97.50.54 (0.25)1.71 (1.04--2.81)0.033WHO Score\*− 0.47 (0.23)0.63 (0.4--0.99)0.044Sarcopenia\*\*\*\*0.96 (0.24)2.61 (1.61--4.24)\< 0.001Weight loss\<=5%−0.35 (0.24)0.71 (0.44--1.13)0.142Weight loss\<=10%−0.13 (0.26)0.88 (0.53--1.45)0.604Albumin levels\<=35(g/l)−0.23 (0.31)0.79 (0.43--1.45)0.449BMI \< =180.61 (0.33)1.84 (0.96--3.53)0.061Masculine Sex0.53 (0.34)1.7 (0.87--3.3)0.116Age \< =65−0.3 (0.23)0.74 (0.47--1.16)0.186Histology \*\*\*0.32 (0.29)1.38 (0.77--2.47)0.277SUV max\<=12.3−0.33 (0.23)0.72 (0.46--1.13)0.154TVol40 \< =9.9−0.44 (0.28)0.64 (0.37--1.12)0.116Muscular Mean Density \< =41 (for BMI \< 25)0.02 (0.43)1.02 (0.43--2.41)0.957Muscular Mean Density \< =33 (for BMI \> 25)1.11 (0.74)3.02 (0.71--12.82)0.116Metastasis \*\*−0.33 (0.33)0.72 (0.38--1.37)0.315\*Versus patients with WHO score \> 0. \*\* Versus patient without metastasis. \*\*\*SCC versus OA. \*\*\*\* Defined as SMI \< 38.3 cm^2^/m^2^ for women and \< 52.4 cm^2^/m^2^ for menTable 4Hazard ratio and 95% CI for proportional hazard models assessing the effect of variables associated with survival (multivariate analysis)Coefficient (SE)Hazard ratio (95%CI)pBMI \< =210.08 (0.3)1.09 (0.6--1.96)0.78NRI \< =97.50.34 (0.28)1.4 (0.81--2.42)0.225WHO Score\*−0.18 (0.28)0.83 (0.48--1.44)0.504Sarcopenia\*\*\*\*0.84 (0.32)2.32 (1.25--4.34)0.008\*Versus patients with WHO score \> 0. \*\*\*\* Defined as SMI \< 38.3 cm^2^/m^2^ for women and \< 52.4 cm^2^/m^2^ for men

ROC curve analyses are shown on Fig. [3](#Fig3){ref-type="fig"}. The Area Under the Curve (AUC) was 0.64 (*p* = 0.03) for SMI over the whole study population (Fig. [3](#Fig3){ref-type="fig"} (a)). Of note, according to various criteria used to optimize sensibility and specificity, optimal cut-points varied from 50.55 (Se = 63, Sp = 62, PPV = 86, NPV = 32) to 51.98 cm^2^/m^2^ (Se = 70, Sp = 62, PPV = 87, NPV = 36) for the whole sample, and from 53.63 (Se = 74, Sp = 73, PPV = 92, NPV = 39) to 53.84cm^2^/m^2^ (Se = 76, Sp = 73, PPV = 93, NPV = 41) for men. The AUC for SMI over the 16 women included in the study was 0.4 (*p* = 0.28) so that optimal cut-point could not be investigated. Similarly, the AUCs for VFML3 and SCFML3 (Fig. [3](#Fig3){ref-type="fig"} (b) and (c)) were 0.54 (*p* = 0.28) and 0.55 (*p* = 0.22), respectively. Fig. 3ROC curves for SMI (**a**), SCFML (**b**) and VFM (**c**)

Discussion {#Sec8}
==========

The present study demonstrates that the presence of sarcopenia is strongly associated to an increased risk of death in 97 patients having received curative-intent chemo-radiotherapy for LAOC. We have confirmed the observations made in operated oesophageal carcinoma patients \[[@CR11], [@CR12]\] and a previous study on chemoradiotherapy \[[@CR23]\]. The prevalence of sarcopenia (44%) was consistent with the literature (26--57%) \[[@CR11], [@CR17]--[@CR22]\],There was a difference for metastasis status between sarcopenic and non sarcopenic patients, although not significant. It could be a bias for survival comparison. However, of the 17 patients, there were 15 patients staged as M1 because of a non-regional positive lymph node involvement on PET-CT and 2 patients with a single pulmonary metastasis (one in each group). All these were considered accessible to a loco-regional treatment in a multidisciplinary team meeting, and we chose to include them as a reflection of the current medical practice.

The usual nutritional features serum albumin level, BMI, and weight loss were not significantly associated with survival on multivariate analysis, which may be explained by limited statistical power in our study. Indeed, BMI \< 18 appeared not to be statistically associated with survival (*p* = 0.061) with an HR of 1.84 \[0.96--3.53\]. Moreover, trends concerning serum albumin levels and weight loss are in agreement with well-known results in the literature.

We performed an internal validation on our sample, in order to confirm the reliability of the model. Since the sample size was limited, we chose to use a boostrapping method. Internal validation showed an acceptable degree of reliability of the model, by using a boostrap method as recommended by TRIPOD statement for prediction development when dealing with small samples. External validation could not have however been performed in our study. The proposed statistical model thus deserves to be validated in other cohorts of patients.

The relation between sarcopenia and increased mortality is not fully understood. Increased susceptibility to nosocomial infection \[[@CR28]\], baseline systemic inflammation associated to higher rates of metastasis and progression \[[@CR29]\], and variations of chemotherapy volume distribution with sarcopenia \[[@CR30], [@CR31]\] are possible explanations. For example, the presence of sarcopenia was associated to higher 5-FU-induced toxicities \[[@CR14]\]. A limitation of our study is that we could not collect data about toxicity. These data should be analysed on a prospective clinical trial which is to be confirmed. Sarcopenia can also be considered as reflect of the clinical state of the patient.

To conclude, sarcopenia assessed by CT sequence on PET-CT at baseline is an independent and robust prognostic factor of overall survival in patients with LAOC treated exclusively by radiochemotherapy, more prognostic than WHO score, BMI, albumin levels and weight loss. These easily gathered imaging features can identify an at-risk population who need a specific therapy. Despite this, evaluation of sarcopenia is not currently used because of the necessity of manual segmentation. Automatic segmentation software is necessary to expand its use.
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